Delaying latency to seizure by combinations of ketone supplements
Provided herein are compositions and methods for preventing central nervous system oxygen toxicity in a subject.
1. A method of treating or preventing central nervous system oxygen toxicity (CNS-OT) in a subject in need thereof, the method comprising administering a composition comprising a therapeutically effective amount of a ketone ester and a medium chain triglyceride to the subject, wherein administering the composition comprises administering a daily amount of about 1 mg/kg to about 5 g/kg bodyweight of each of the ketone ester and MCT.
2. The method of claim 1 , wherein the composition prevents, delays the onset of, or reduces the severity of tonic-clonic seizures in the subject.
3. The method of claim 1 , wherein the ketone ester is 1,3-butanediol-acetoacetate diester.
4. The method of claim 1 , wherein the ketone ester and the medium chain triglyceride have an approximate 1:1 ratio.
5. The method of claim 1 , wherein the composition further comprises a ketone salt.
6. The method of claim 5 , wherein the ketone salt is a β-hydroxybutyrate salt.
7. The method of claim 6 , wherein the ketone salt is a β-hydroxybutyrate mineral salt.
8. The method of claim 7 , wherein the β-hydroxybutyrate mineral salt is a Na + Ca 2+ β-hydroxybutyrate mineral salt.
9. The method of claim 8 , wherein the ketone salt and the medium chain triglyceride have an approximate 1:1 ratio.
10. A method of treating or preventing seizures in a subject in need thereof, the method comprising administering a composition comprising a therapeutically effective amount of a ketone ester and a medium chain triglyceride to the subject,
where in administering the composition comprises administering a daily amount of about 1 mg/kg to about 5 g/kg bodyweight of each of the ketone ester and MCT.
11. The method of claim 10 , wherein the composition delays the onset of or reduces the severity of seizures in the subject.
12. The method of claim 10 , wherein the seizure is from epilepsy.
13. The method of claim 10 , wherein the ketone ester is 1,3-butanediol-acetoacetate diester.
14. The method of claim 10 , wherein the ketone ester and the medium chain triglyceride have an approximate 1:1 ratio.
15. The method of claim 10 , wherein the composition further comprises one or more ketogenic compounds is a ketone salt.
16. The method of claim 15 , wherein the ketone salt is κ β-hydroxybutyrate salt.
17. The method of claim 16 , wherein the ketone salt is a β-hydroxybutyrate mineral salt.
18. The method of claim 17 , wherein the β-hydroxybutyrate mineral salt is a Na + Ca 2+ β-hydroxybutyrate mineral salt.
19. The method of claim 15 , wherein the ketone salt and the medium chain triglyceride have an approximate 1:1 ratio.
20. A method of treating or preventing epileptic seizures in a subject in need thereof, the method comprising administering a composition comprising a therapeutically effective amount of a ketone supplement comprising a ketone ester to the subject.